H.C. Wainwright Reiterates Neutral Rating, $2 PT on Akebia Therapeutics (AKBA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| AKEBIA THERAPEUTICS (NASDAQ: AKBA) | Delayed: 0.69 -0.04 (5.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.73 | 52 Week High | $13.20 | |||
| Open | $0.75 | 52 Week Low | $7.00 | |||
| Day High | $0.75 | P/E | N/A | |||
| Day Low | $0.66 | EPS | $0.00 | |||
| Volume | 10,830,607 | |||||
